Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Gilbert, Mark R.
Hess, Kenneth R.
Lagrone, Lore
Groves, Morris D.
Levin, Victor A.
De Groot, John Frederick
Loghin, Monica Elena
Puduvalli, Vinay K.
Fisch, Michael
Giglio, Pierre
Colman, Howard
Conrad, Charles A.
Aldape, Kenneth D.
Yung, W. K. Alfred
Anderson, M. D.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Redwood City Med Ctr, Redwood City, CA USA
[3] MUSC Hollings Canc Ctr, Charleston, SC USA
[4] Univ Utah, Salt Lake City, UT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2003
引用
收藏
页数：1
相关论文
共 14 条
  • [1] A phase I study for a factorial design of dose-dense temozolomide (TMZ) alone and in combination with permutations of thalidomide (Thal), isotretinoin (CRA) and/or celecoxib (Cel) as post-chemoradiation adjuvant therapy for newly diagnosed glioblastoma (GBM)
    Gilbert, M. R.
    Gonzalez, J.
    Hunter, K.
    Hess, K.
    Chang, E.
    Puduvalli, V.
    Groves, M.
    Colman, H.
    Conrad, C.
    Levin, V.
    Woo, S.
    Mahajan, A.
    Hsu, S.
    de Groot, J.
    Yung, W. K. A.
    NEURO-ONCOLOGY, 2006, 8 (04) : 442 - 443
  • [2] Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma
    Penas-Prado, Marta
    Hess, Kenneth R.
    Fisch, Michael J.
    Lagrone, Lore W.
    Groves, Morris D.
    Levin, Victor A.
    De Groot, John F.
    Puduvalli, Vinay K.
    Colman, Howard
    Volas-Redd, Gena
    Giglio, Pierre
    Conrad, Charles A.
    Salacz, Michael E.
    Floyd, Justin D.
    Loghin, Monica E.
    Hsu, Sigmund H.
    Gonzalez, Javier
    Chang, Eric L.
    Woo, Shiao Y.
    Mahajan, Anita
    Aldape, Kenneth D.
    Yung, W. K. Alfred
    Gilbert, Mark R.
    NEURO-ONCOLOGY, 2015, 17 (02) : 266 - 273
  • [3] A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma
    Gilbert, Mark R.
    Gonzalez, Javier
    Hunter, Kathy
    Hess, Kenneth
    Giglio, Pierre
    Chang, Eric
    Puduvalli, Vinay
    Groves, Morris D.
    Colman, Howard
    Conrad, Charles
    Levin, Victor
    Woo, Shaio
    Mahajan, Anita
    de Groot, John
    Yung, W. K. Alfred
    NEURO-ONCOLOGY, 2010, 12 (11) : 1167 - 1172
  • [4] RTOG 0525: A RANDOMIZED PHASE III TRIAL COMPARING STANDARD ADJUVANT TEMOZOLOMIDE (TMZ) WITH A DOSE-DENSE (DD) SCHEDULE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Gilbert, Mark R.
    Wang, Meihua
    Aldape, Ken D.
    Stupp, Roger
    Hegi, Monika
    Jaeckle, Kurt A.
    Armstrong, Terri S.
    Wefel, Jeffrey S.
    Won, Minhee
    Blumenthal, Deborah T.
    Mahajan, Anita
    Schultz, Christopher J.
    Erridge, Sara C.
    Brown, Paul D.
    Chakravarti, Arnab
    Curran, Walter J., Jr.
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2011, 13 : 51 - 51
  • [5] RTOG 0525: A randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM).
    Gilbert, M. R.
    Wang, M.
    Aldape, K. D.
    Stupp, R.
    Hegi, M.
    Jaeckle, K. A.
    Armstrong, T. S.
    Wefel, J. S.
    Won, M.
    Blumenthal, D. T.
    Mahajan, A.
    Schultz, C. J.
    Erridge, S. C.
    Brown, P. D.
    Chakravarti, A.
    Curran, W. J.
    Mehta, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Phase II study of adjuvant dose-dense temozolomide (TMZ) for glioblastoma after surgery and radiochemotherapy
    Ramus, Vietti G.
    Tonda, L.
    Sirgiovanni, M. P.
    Addeo, A.
    Monetti, U.
    Coverlizza, S.
    ANNALS OF ONCOLOGY, 2006, 17 : XI60 - XI61
  • [7] Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
    Clarke, Jennifer L.
    Iwamoto, Fabio M.
    Sul, Joohee
    Panageas, Katherine
    Lassman, Andrew B.
    DeAngelis, Lisa M.
    Hormigo, Adilia
    Nolan, Craig P.
    Gavrilovic, Igor
    Karimi, Sasan
    Abrey, Lauren E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3861 - 3867
  • [8] A randomized phase II trial of concurrent temozolomide (TMZ) and radiotherapy (RT) followed by dose-dense compared to metronomic TMZ and maintenance cis-retinoic acid for patients with newly diagnosed glioblastoma multiforme (GBM)
    Clarke, Jennifer
    Sul, Joohee
    DeAngelis, Lisa
    Lassman, Andrew
    Hormigo, Adilia
    Nolan, Craig
    Gavrilovic, Igor
    Gu, Bin
    Panageas, Kathy
    Abrey, Lauren
    NEURO-ONCOLOGY, 2007, 9 (04) : 530 - 530
  • [9] RTOG 0525: Exploratory Subset Analysis from a Randomized Phase III Trial Comparing Standard (std) Adjuvant Temozolomide (TMZ) with a Dose-dense (dd) Schedule for Glioblastoma (GBM)
    Mehta, M. P.
    Wang, M.
    Aldape, K.
    Stupp, R.
    Jaeckle, K. A.
    Blumenthal, D.
    Brown, P.
    Erridge, S.
    Curran, W.
    Gilbert, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S128 - S129
  • [10] RTOG 0625: A RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB WITH EITHER IRINOTECAN (CPT) OR DOSE-DENSE TEMOZOLOMIDE (TMZ) IN RECURRENT GLIOBLASTOMA (GBM)
    Gilbert, Mark R.
    Wang, Meihua
    Aldape, Kern
    Sorensen, A. Gregory
    Mikkelsen, Tom
    Bokstein, Felix
    Woo, Shaio Y.
    Chmura, Steven J.
    Choucair, Ali K.
    Mehta, Minesh
    NEURO-ONCOLOGY, 2010, 12 : 39 - 39
12